If you want to distinguish your goods, services or both from those of another company, you may need a trademark or trade name. Find out what they are, what their registration procedure is and what it involves.
Information on the deadlines for filing applications for transformation of European Union trademarks into Spanish national trademarks. See more
If you have a new device, product or procedure that solves a technical problem or has a practical advantage, there are different ways to protect it in Spain and other countries. Find out how.
Does your innovation lie in the aesthetics, ornamentation or appearance of your product? Protect it through industrial design. Find out what rights registration confers and how to proceed.
Geographical indications protect the name of a product that has a specific geographical origin and owes its qualities, characteristics or reputation to its particular origin. Find out what they are, how the registration process works and what benefits they provide.
Patents published worldwide are a valuable source of scientific, technical and commercial information.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
If you are an entrepreneur or a company and you want to boost and improve the profitability of your business by adequately protecting the intangible assets of your organisation, in this space you will find what you need.
278
results.
Updated on
13/11/2026 [06:58:00]
Absstract of: US20260357191A1
The present invention relates to a modified live attenuated strain of Salmonella, said strain comprising at least one chromosomally integrated synthetic polynucleotide sequence inserted into a pre-determined pseudogenomic location, said sequence comprising at least one defined recombination site for the introduction of a heterologous polynucleotide sequence encoding a polypeptide, wherein said chromosomally integrated synthetic polynucleotide sequence is located within at least one genomic locus as defined by any one of SEQ ID NOs: 1-30, or a sequence comprising at least 70% identity to any one of SEQ ID NOs: 1-30. The present invention also relates to a vaccine composition comprising the modified strain and various uses and methods thereof.
Absstract of: US20260355260A1
The present disclosure relates to a recombinant expression vector for secretion of conantokin-G and an attenuated Salmonella strain transformed therewith, and provides: an attenuated Salmonella strain transformed with a recombinant expression vector including a flgM gene and a conantokin-G gene; an anticancer pharmaceutical composition including the attenuated Salmonella strain as an active ingredient; and a recombinant expression vector capable of enhancing secretion capacity for conantokin-G.
Absstract of: US20260354407A1
Formulations of egg powders with avian antibodies that act as mucosal protectants are provided. The formulations are effective for protecting the mucosal membranes in the pharyngeal area of an individual from viral infections. Formulations effective for reducing infections of SARS-CoV-2 in individuals are provided. Formulations are also effective for reducing transmission of viral disease. The formulations are tablets, candies, gummies, throat lozenges, and powders for administering to the pharyngeal area. Methods for administering the formulations for reducing viral disease such as Covid-19 are disclosed.
Absstract of: CN122998332A
本发明涉及基于FliC/CpG佐剂系统的HSV‑2三价黏膜疫苗组合物及其应用，属于生物医药技术领域。该疫苗包括包括鼠伤寒沙门氏菌鞭毛蛋白FliC、CpG寡核苷酸和HSV‑2 gC2‑gD2‑gE2三抗原串联重组蛋白；其中，鼠伤寒沙门氏菌鞭毛蛋白FliC的氨基酸序列如SEQ ID NO.1所示；CpG寡核苷酸的序列如SEQ ID NO.3所示。本发明基于FliC/CpG佐剂系统的HSV‑2三价黏膜疫苗经滴鼻免疫BALB/c小鼠后，能有效诱导小鼠黏膜免疫并对HSV‑2/KM‑1攻毒有显著保护效力。
Absstract of: AU2025262750A1
The present invention relates to a live attenuated Gram-negative bacterium comprising a modified hlyCABD operon, wherein the modified hlyCABD operon is split into a first segment and a second segment, the first segment being operably linked to a first independently controlled promoter, wherein the first independently controlled promoter is a strong constitutive promoter or a strong vacuole-induced promoter, and the second segment being operably linked to a second independently controlled promoter, wherein the second independently controlled promoter is a strong vacuole-induced promoter, and wherein the first segment comprises a heterologous polynucleotide encoding a lysin upstream of a hlyAs translocation sequence, wherein the heterologous polynucleotide encoding one or more cargo molecules replaces a hlyA gene, and wherein the second segment comprises hly genes involved in secretion.
Absstract of: WO2026222548A1
Vaccine candidates designed to protect poultry against infection with Salmonella enterica serovars include multiple antigenic polypeptide fragments of Salmonella iron acquisition proteins, such as the iron-regulated outer membrane proteins FepA, CirA, IroN and FhuA. The Salmonella antigenic polypeptides are displayed on the surface of protein nanoparticles, such as encapsulin or Brucella spp. lumazine synthase, and can be expressed in plants such as Nicotiana benthamiana.
Absstract of: AU2025260066A1
The present invention relates to a live attenuated Gram-negative bacterium modified to enable enhanced vacuole escape. In particular, the invention relates to a live attenuated Gram-negative bacterium comprising a heterologous polynucleotide encoding a prokaryotic disulfide bond isomerase, or functional fragment thereof, wherein said heterologous polynucleotide encoding the prokaryotic disulfide bond isomerase is operably linked to a promoter, or a live attenuated Gram-negative bacterium comprising an endogenous prokaryotic disulfide bond isomerase, or functional fragment thereof, wherein the endogenous prokaryotic disulfide bond isomerase is upregulated compared to its basal level expression.
Absstract of: CN122979483A
本发明公开了一种viral enhancin protein基因及其引物探针组合和在肠炎沙门菌检测中的应用。viral enhancin protein基因的核苷酸序列如SEQ ID NO.2所示。本发明无需经过复杂的分菌、生化鉴定及血清学鉴定即可区分出肠炎沙门菌，极大缩短病原检测时间。与传统方法相比，实验条件要求低，可对病原进行定量检测，具有开发为快速检测试剂盒的良好潜力。
Absstract of: CN122954935A
本发明公开了一种通用型细菌外膜囊泡递送系统GMMA，涉及合成生物学疫苗递送技术领域，本发明先以脱氧胆酸钠法从革兰氏阴性菌提取直径 50‑100 nm 的外膜囊泡OMV，再经 1‑乙基‑3‑(3‑二甲基氨基丙基)‑碳二亚胺将三聚乙二醇胺生物素偶联至囊泡表面；将经 A67D、G71K、A82N、G84Q、S101R、A105K 六位点突变并截短为 114 aa 的单体亲和素与目标抗原通过五肽 GGGGS 融合表达，所得亲和素‑抗原融合蛋白与生物素化囊泡自组装形成 GMMA，结合亲和力 KD=6.6×10‑8；该系统无需菌株多基因改造即可加载一种或多种抗原，装载过程为可逆插拔式，囊泡结构完整，制备简便，安全性良好，适用于疫苗及其他抗原递送领域。
Absstract of: CN122937203A
本发明涉及一种基于鞭毛‑芽胞复合材料的口服疫苗制备方法和应用，有效解决传统注射型疫苗依从性差、黏膜免疫反应低的问题。首先，通过对细菌进行酸化处理、超速离心、硫酸铵盐析等步骤，提取具有天然免疫佐剂活性的鞭毛。以阳离子壳寡糖为连接臂，借助静电相互作用将鞭毛、抗原蛋白、抗原呈递细胞靶头（昆布多糖）组装为复合物，并修饰在益生菌芽孢表面，即得基于鞭毛‑芽胞复合材料的口服疫苗。本发明制备条件温和，生产成本低，制备的基于鞭毛‑芽胞复合材料的口服疫苗可有效激发肠道黏膜免疫应答，预防黏膜病原体的感染，有实际的推广应用价值。
Absstract of: US20260317405A1
The invention relates to methods of treating or preventing a disease or condition caused by or associated with a gram-negative bacterial infection in a subject in need thereof and compositions for use in such methods. More particularly, the present invention relates to agents and compositions, including concanavalin A, lactoferrin, colostrum and Ig from colostrum for use in the treatment or prevention of a disease or condition caused by or associated with a gram-negative bacterial infection and methods of using such agents and compositions.
Absstract of: US20260318913A1
0000 A portable detection system for detecting a pathogen or virus, the portable detection system comprising: at least one light source for generating an input optical signal; at least one optical sensor comprising at least one optical fibre having at least one tapered sensing region with at least one coating that reacts with a pathogen being detected, wherein the optical sensor is arranged to receive the input optical signal, communicate the input optical signal through the tapered sensing region and communicate an output optical signal from the tapered sensing region; at least one photodetector for detecting power intensity of the output optical signal, wherein the photodetector is arranged to generate an output signal based on a change in power intensity of the output power at a resonant wavelength that corresponds with the pathogen; and at least one microcontroller for controlling the light source, optical sensor and photodetector; wherein the portable detection system is arranged to cause an output to be generated based on the output signal, wherein the output is associated with the pathogen being detected.
Absstract of: US20260318915A1
0000 The present disclosure discloses an indirect ELISA kit for detecting whether hosts are infected with Listeria monocytogenes and/or Listeria ivanovii. The coated antigens are the recombinant Listeria monocytogenes surface protein ActA, the outer membrane protein SmcL shared by serotype 4 h of Listeria monocytogenes and Listeria ivanovii, and the unique outer membrane protein I-inIH of Listeria ivanovii. An indirect ELISA method for each of these three antigens is established. By combining these three methods, the levels of ActA, SmcL and I-inIH antibodies in serum samples can be effectively monitored to detect listeriosis caused by Listeria monocytogenes and/or Listeria ivanovii. With high sensitivity, specificity, and stability, the kit provides an effective method for epidemiologic investigation and diagnosis of listeriosis.
Absstract of: US20260315404A1
0000 A prophylactic vaccine composition that is intended for mammals and birds comprises a killed whole bacterium, the bacterium being covered with a cationic agent, in particular, cationic nanoparticles.
Absstract of: CN117398456A
The invention discloses a tumor neoantigen vaccine system specifically labeled with heterologous protein and application of the tumor neoantigen vaccine system, the vaccine system is composed of a heterologous protein mRNA vaccine and a recombinant oncolytic virus, and the heterologous protein mRNA vaccine is used for inducing an organism to generate heterologous protein specific memory T cells; the recombinant oncolytic virus is used for promoting the tumor to express the microorganism-derived tumor neoantigen, when the pre-immunized memory T cells detect the marked specific neoantigen, the tumor expressing the neoantigen is quickly activated and killed, the release of the autoantigen of the tumor is promoted, and the dendritic cells phagocytize the antigen to further start the anti-tumor response, so that the anti-tumor effect is achieved. The systemic anti-tumor immune effect is activated through epitope expansion; the treatment strategy is applied to preparation of tumor immunotherapy drugs, and can quickly recognize and kill tumor cells and activate the anti-tumor immune effect.
Absstract of: CN109415772A
Provided herein are methods and compositions for detecting Salmonella Typhimurium in a sample.
Absstract of: WO2026208522A1
A microbial antibodyomics technology-based system and method for directed isolation of intestinal bacteria. Said system comprises a negative pressure driving mechanism, a filtration and impurity removal device (100) used for performing filtration and impurity removal treatment on a feces sample, a harmful bacterium adsorption assembly (210) used for removing harmful bacteria in a microbial mixture liquid, a beneficial bacterium enrichment assembly (220) used for performing positive enrichment treatment on beneficial bacteria in the microbial mixture liquid, a beneficial bacterium dissociation assembly (234) used for performing dissociation on beneficial bacterium-coupled bodies, and a beneficial bacterium collection bottle (240) used for collecting beneficial bacteria. The negative pressure driving mechanism is used for enabling the beneficial bacteria in the feces sample to automatically enter the beneficial bacterium collection bottle (240) after sequentially passing through the filtration and impurity removal device (100), the beneficial bacterium enrichment assembly (220) and the beneficial bacterium dissociation assembly (234). Therefore, directly and selectively screening target beneficial bacteria from feces samples is achieved, and the requirements of accurate transplantation of intestinal flora and accurate treatment of specifically related intestinal diseases in the future can be met.
Absstract of: US20260308603A1
Provided are a recombinant expression vector for secretion of CAT protein and an E. coli strain transformed with the vector. Provided are a recombinant expression vector including a flgM gene, a CAT gene, and a flhDC gene, an E. coli strain transformed with the vector, and a pharmaceutical composition for treating cancer, including the E. coli strain as an active ingredient.
Absstract of: US20260306554A1
0000 The present disclosure relates to a recombinant expression vector for secretion of an IFN-β protein and an attenuated Salmonella strain transformed therewith, and provides: a recombinant expression vector comprising an flgM gene, an IFN-β gene, and an flhDC gene; an attenuated Salmonella strain transformed therewith; and a pharmaceutical composition for cancer treatment, comprising the attenuated Salmonella strain as an active ingredient.
Absstract of: US20260306602A1
Provided herein are vaccine compositions comprising Salmonella antigens conjugated to a capsid, wherein said capsid comprises wild type or native sequence, or said capsid may comprise at least one mutation, such as a non-natural mutation; such compositions being useful in the treatment and prevention of a Salmonella infection (salmonellosis), gastroenteritis, typhoid fever, and/or paratyphoid fever; and may be effective against multiple strains of Salmonella.
Absstract of: US20260309706A1
A method for pathogen detection is also disclosed which includes (i) operating a micropump forcing a first fluid hosting a pathogen-selective antibody from a source to a destination, defining a target, via a microfluidic channel, (ii) operating the micropump to thereby force a second fluid potentially hosting the selective pathogen from the source to the destination, obtaining a signal from the destination indicating a mass change; (iii) comparing the mass change to a predetermined threshold to indicate conditional presence of the pathogen and concentration of the pathogen, (iv) operating the micropump forcing a third fluid hosting a pathogen-selective photoluminescent label from the source to the destination, (v) activating a light excitation subsystem, (vi) capturing images from the target; and (vii) analyzing the images to determine presence of the label thus double-confirming a) presence of the pathogen, and b) concentration of the pathogen.
Absstract of: US20260301973A1
Certain pathogens are known to cause infection in humans or other living hosts. However, harmful pathogens may have thousands of distinct strains or serovars, only a fraction of which may cause a severe or life-threatening infection. Timely identification of strains which are most likely to cause serious infections is problematic. A system and a method are disclosed which provide a diagnostic protocol for identifying virulence groups in one or more pathogens of interest based on genomic features and/or identifying pathogenic markers of higher virulence in hazardous pathogens such as Salmonella enterica which may be used in combination with pathogen surveillance data to optimize the identification of pathogens of public risk and health concern so that the most effective interventions may be selected and applied in a timely manner.
Absstract of: WO2025177207A1
A recombinant tumor-homing bacterium having constitutive prokaryotic expression cassettes comprising two or more homologous cancer associated antigens, each of the respective homologous cancer associated antigens associated with a transport signal from a distinct transport system, a regulating expression cassette encoding a regulator and an aspirin-inducible prokaryotic expression cassette encoding a set of immunomodulator fusion peptides operably linked to an inducible promoter, each of said immunomodulator fusion peptides comprising a heterologous immunomodulator associated with a secretion signal, said heterologous immunomodulator selected from a list consisting of: LIGHT, GMCSF, SIRP alpha, and IL18.
Absstract of: US20260298925A1
Provided are non-naturally occurring systems, methods, and compositions for the detection of microbes. The disclosure relates to the detection of an antigen specific to a microbe, such as a foodborne, an environment-borne, and a bloodborne bacteria, using capture antibody and moiety, detector antibody and moiety, and a light-emitting particle.
Nº publicación: EP4814110A1 30/09/2026
Applicant:
JIANGSU TARGETPHARMA LABORATORIES INC [CN]
Jiangsu Targetpharma Laboratories Inc.
Absstract of: EP4814110A1
0001 Provided are a preparation method and application of cryo-shocked monocytes or macrophages loaded with attenuated Salmonella. The method comprises loading engineered attenuated Salmonella into monocytes or macrophages, followed by cryo-shock treatment of monocytes or macrophages loaded with the strain using liquid nitrogen. The method for preparing the cryo-shocked immune cells loaded with the strain is simple and easy to operate, and solves the source problem of the monocytes or macrophages loaded with engineered attenuated Salmonella is solved, thus having good application prospects. This strategy improves the biosafety of bacteria-based anti-tumor therapy by avoiding bacterial exposure and heterologous stimulation; and high intratumoral strain titer promotes an anti-tumor immune response, thereby achieving stronger anti-tumor efficacy.
BOPI
Electronic site
